See more : Frontier Transport Holdings Limited (FTH.JO) Income Statement Analysis – Financial Results
Complete financial analysis of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Yiren Digital Ltd. (YRD) Income Statement Analysis – Financial Results
- Dr. Lal PathLabs Limited (LALPATHLAB.NS) Income Statement Analysis – Financial Results
- Installux S.A. (ALLUX.PA) Income Statement Analysis – Financial Results
- Banco ABC Brasil S.A. (ABCB4.SA) Income Statement Analysis – Financial Results
- Lazard Growth Acquisition Corp. I (LGACU) Income Statement Analysis – Financial Results
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ)
About China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in the People's Republic of China and internationally. It also provides related health services. The company offers OTC products, including cold, skin, gastrointestinal, cough relieving, orthopedics, and pediatrics drugs; prescription drug products in traditional Chinese medicine, tumors, cardiovascular and cerebrovascular, digestive system, orthopedics, and pediatrics; Chinese medicine injections; formula granules; and anti-infective drugs. It sells its products under 999 family medicine brands, Sanjiuweitai series, 999 Ganmaoling series, 999 dermatitis series, and other products. The company was formerly known as Sanjiu Pharmaceutical Co., Ltd. and changed its name to China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. in February 2010. The company was founded in 1999 and is based in Shenzhen, the People's Republic of China. China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a subsidiary of China Resources (Holdings) Co., Ltd.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.74B | 18.08B | 15.32B | 13.64B | 14.70B | 13.43B | 11.12B | 8.98B | 7.90B | 7.28B | 7.80B | 6.89B | 5.53B | 4.37B | 4.85B | 4.32B | 3.40B | 2.87B | 2.97B | 2.46B | 2.67B | 2.17B | 1.87B | 1.83B | 1.48B | 1.43B | 1.11B |
| Cost of Revenue | 11.73B | 8.31B | 6.17B | 5.12B | 4.83B | 4.16B | 3.91B | 3.36B | 3.07B | 2.81B | 3.09B | 2.68B | 2.27B | 1.69B | 2.40B | 2.35B | 1.78B | 1.55B | 1.56B | 1.36B | 1.35B | 1.10B | 917.00M | 1.01B | 635.45M | 604.72M | 487.21M |
| Gross Profit | 13.01B | 9.77B | 9.15B | 8.52B | 9.87B | 9.27B | 7.21B | 5.62B | 4.83B | 4.46B | 4.71B | 4.21B | 3.26B | 2.68B | 2.46B | 1.96B | 1.62B | 1.32B | 1.41B | 1.10B | 1.32B | 1.06B | 950.32M | 822.81M | 840.97M | 821.16M | 622.62M |
| Gross Profit Ratio | 52.60% | 54.02% | 59.72% | 62.46% | 67.15% | 69.02% | 64.86% | 62.57% | 61.18% | 61.35% | 60.39% | 61.14% | 58.96% | 61.37% | 50.62% | 45.49% | 47.59% | 45.90% | 47.49% | 44.61% | 49.38% | 49.05% | 50.89% | 45.01% | 56.96% | 57.59% | 56.10% |
| Research & Development | 767.60M | 593.94M | 560.20M | 459.84M | 441.88M | 355.84M | 297.34M | 286.79M | 236.46M | 231.80M | 198.37M | 159.65M | 102.95M | 71.55M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 351.36M | 253.99M | 253.81M | 236.95M | 237.20M | 175.94M | 168.78M | 156.56M | 145.05M | 125.15M | 177.28M | 141.74M | 111.52M | 83.65M | 367.63M | 311.34M | 221.28M | 241.50M | 328.47M | 768.25M | 389.95M | 396.97M | 443.74M | 263.12M | 156.69M | 224.54M | 203.54M |
| Selling & Marketing | 5.67B | 5.08B | 5.02B | 5.02B | 6.55B | 6.47B | 4.75B | 3.28B | 2.68B | 2.41B | 2.41B | 2.20B | 1.76B | 1.36B | 1.17B | 960.69M | 814.86M | 639.39M | 695.07M | 601.88M | 502.92M | 357.57M | 348.39M | 345.81M | 445.44M | 421.81M | 268.35M |
| SG&A | 8.54B | 5.33B | 5.28B | 5.25B | 6.79B | 6.64B | 4.92B | 3.44B | 2.82B | 2.54B | 2.59B | 2.34B | 1.87B | 1.44B | 1.53B | 1.27B | 1.04B | 880.89M | 1.02B | 1.37B | 892.87M | 754.54M | 792.13M | 608.93M | 602.12M | 646.34M | 471.89M |
| Other Expenses | 0.00 | 792.48M | 662.24M | 625.10M | 678.33M | 15.40M | 7.79M | 175.47M | 91.92M | 39.10M | 25.73M | 75.38M | 28.10M | 74.15M | 22.21M | 16.51M | 59.74M | -13.10M | 8.45M | -9.77M | 4.54M | 9.19M | 47.44M | 59.35M | 52.23M | 46.35M | 45.95M |
| Operating Expenses | 9.42B | 6.72B | 6.50B | 6.34B | 7.91B | 7.55B | 5.66B | 4.29B | 3.56B | 3.24B | 3.29B | 2.95B | 2.33B | 1.76B | 1.55B | 1.31B | 1.05B | 894.42M | 1.04B | 1.38B | 909.95M | 764.35M | 797.31M | 616.06M | 605.24M | 649.49M | 474.89M |
| Cost & Expenses | 20.99B | 15.03B | 12.67B | 11.46B | 12.74B | 11.71B | 9.57B | 7.65B | 6.62B | 6.06B | 6.38B | 5.63B | 4.59B | 3.45B | 3.95B | 3.66B | 2.83B | 2.45B | 2.60B | 2.74B | 2.26B | 1.87B | 1.71B | 1.62B | 1.24B | 1.25B | 962.10M |
| Interest Income | 113.60M | 73.48M | 66.99M | 73.74M | 22.77M | 31.62M | 9.96M | 12.35M | 21.87M | 24.40M | 29.93M | 24.25M | 27.43M | 18.37M | 13.10M | 10.59M | 18.17M | 12.04M | 44.60M | 61.00M | 65.29M | 66.48M | 141.66M | 78.78M | -0.21 | -0.15 | -0.09 |
| Interest Expense | 85.17M | 21.23M | 13.27M | 5.09M | 4.41M | 25.84M | 27.98M | 28.16M | 27.88M | 27.61M | 22.56M | 8.80M | 10.50M | 1.81M | 9.60M | 14.36M | 120.79M | 198.76M | 204.68M | 203.53M | 189.77M | 172.25M | 157.60M | 102.79M | 25.09M | 29.40M | 21.60M |
| Depreciation & Amortization | 853.71M | 571.41M | 524.58M | 426.72M | 369.80M | 376.25M | 341.53M | 303.79M | 233.70M | 234.80M | 231.77M | 224.74M | 133.60M | 117.44M | 105.55M | 83.14M | 68.96M | 83.63M | 72.70M | 90.45M | 64.22M | 63.57M | 52.68M | 71.64M | 56.49M | 27.78M | 78.22M |
| EBITDA | 4.69B | 3.55B | 2.98B | 2.49B | 2.93B | 2.12B | 1.87B | 1.79B | 1.82B | 1.55B | 1.60B | 1.52B | 1.09B | 1.15B | 1.02B | 744.92M | 600.15M | 491.08M | 451.89M | -385.53M | 526.86M | 425.03M | 380.56M | 353.90M | 290.51M | 171.66M | 176.74M |
| EBITDA Ratio | 18.95% | 20.20% | 20.80% | 19.89% | 21.50% | 15.89% | 17.08% | 20.37% | 23.05% | 21.47% | 21.91% | 23.00% | 20.31% | 26.46% | 21.61% | 17.87% | 21.25% | 17.12% | 15.22% | -15.66% | 19.70% | 19.63% | 20.38% | 23.02% | 19.68% | 11.99% | 15.92% |
| Operating Income | 3.75B | 2.95B | 2.46B | 2.07B | 2.53B | 1.70B | 1.51B | 1.29B | 1.44B | 1.23B | 1.41B | 1.26B | 926.84M | 962.63M | 884.97M | 634.99M | 325.57M | 258.09M | 193.27M | -649.82M | 279.79M | 185.68M | 126.72M | 196.25M | 208.26M | 143.24M | 98.52M |
| Operating Income Ratio | 15.17% | 16.30% | 16.04% | 15.18% | 17.20% | 12.69% | 13.58% | 14.40% | 18.26% | 16.88% | 18.10% | 18.32% | 16.77% | 22.05% | 18.24% | 14.71% | 9.58% | 9.00% | 6.51% | -26.40% | 10.46% | 8.57% | 6.79% | 10.74% | 14.11% | 10.05% | 8.88% |
| Total Other Income/Expenses | 1.08M | 10.35M | -28.30M | -10.79M | 40.92M | 15.40M | 7.79M | 159.47M | 87.48M | 31.57M | 21.92M | 20.71M | 20.51M | 71.40M | 19.49M | 9.41M | -119.43M | -212.16M | -198.12M | -395.59M | -6.92M | 3.53M | 43.55M | -16.78M | 51.66M | 46.03M | 45.59M |
| Income Before Tax | 3.75B | 2.96B | 2.43B | 2.06B | 2.57B | 1.72B | 1.52B | 1.45B | 1.53B | 1.26B | 1.43B | 1.28B | 948.11M | 1.03B | 904.46M | 646.00M | 384.43M | 208.69M | 174.50M | -679.50M | 272.87M | 189.21M | 170.27M | 248.42M | 259.93M | 189.27M | 144.11M |
| Income Before Tax Ratio | 15.18% | 16.39% | 15.86% | 15.10% | 17.47% | 12.80% | 13.65% | 16.18% | 19.35% | 17.31% | 18.37% | 18.62% | 17.16% | 23.69% | 18.64% | 14.97% | 11.31% | 7.28% | 5.88% | -27.60% | 10.20% | 8.74% | 9.12% | 13.59% | 17.61% | 13.27% | 12.98% |
| Income Tax Expense | 580.97M | 466.43M | 348.22M | 441.89M | 429.55M | 244.01M | 191.83M | 245.44M | 254.30M | 187.46M | 218.34M | 201.69M | 132.99M | 174.92M | 142.87M | 104.85M | 100.33M | 42.13M | 59.92M | 39.31M | 49.84M | 35.76M | 46.14M | 42.67M | 29.46M | 30.20M | 28.63M |
| Net Income | 2.85B | 2.45B | 2.06B | 1.60B | 2.11B | 1.43B | 1.30B | 1.20B | 1.25B | 1.04B | 1.18B | 1.01B | 760.45M | 815.98M | 709.49M | 500.09M | 279.80M | 164.92M | 119.93M | -720.80M | 208.80M | 165.02M | 121.03M | 201.58M | 220.22M | 150.83M | 98.80M |
| Net Income Ratio | 11.53% | 13.54% | 13.41% | 11.71% | 14.37% | 10.67% | 11.71% | 13.34% | 15.81% | 14.24% | 15.14% | 14.72% | 13.76% | 18.69% | 14.62% | 11.59% | 8.23% | 5.75% | 4.04% | -29.28% | 7.81% | 7.62% | 6.48% | 11.03% | 14.92% | 10.58% | 8.90% |
| EPS | 2.23 | 2.50 | 2.10 | 1.63 | 2.14 | 1.46 | 1.33 | 1.22 | 1.28 | 1.06 | 1.13 | 1.04 | 0.78 | 0.83 | 0.72 | 0.51 | 0.29 | 0.22 | 0.12 | -0.74 | 0.21 | 0.17 | 0.12 | 0.16 | 0.22 | 0.15 | 0.10 |
| EPS Diluted | 2.23 | 2.50 | 2.10 | 1.63 | 2.14 | 1.46 | 1.33 | 1.22 | 1.28 | 1.06 | 1.13 | 1.04 | 0.78 | 0.83 | 0.72 | 0.51 | 0.29 | 0.22 | 0.12 | -0.74 | 0.21 | 0.17 | 0.12 | 0.16 | 0.22 | 0.15 | 0.10 |
| Weighted Avg Shares Out | 1.28B | 978.90M | 978.90M | 978.90M | 978.90M | 978.90M | 978.71M | 978.90M | 975.96M | 977.25M | 981.23M | 981.82M | 974.93M | 983.11M | 985.40M | 977.44M | 972.03M | 978.82M | 979.00M | 979.00M | 979.00M | 979.00M | 979.00M | 979.00M | 979.00M | 979.00M | 979.00M |
| Weighted Avg Shares Out (Dil) | 1.28B | 978.90M | 978.90M | 978.90M | 978.90M | 980.88M | 978.71M | 981.84M | 975.96M | 977.25M | 981.23M | 981.82M | 974.93M | 983.11M | 985.40M | 977.44M | 1.01B | 978.82M | 979.00M | 979.00M | 979.00M | 979.00M | 979.00M | 979.00M | 979.00M | 979.00M | 979.00M |
Source: https://incomestatements.info
Category: Stock Reports